Authors
Latest:
Dr. Kelly on Overcoming Osimertinib Resistance in NSCLC With Bispecific AntibodiesKaren L. Kelly, MD, discusses overcoming osimertinib resistance in patients with non–small cell lung cancer through the use of bispecific antibodies.
Latest:
Lynchpin Molecule for Cancer Metastasis FoundA single molecule called DNA-PKcs may drive metastatic processes that turn cancer from a slowly growing, relatively benign disease to a killer.
Latest:
Dr Reckamp on Emerging EGFR TKIs in EGFR Exon 20 Insertion+ NSCLCKaren L. Reckamp, MD, MS, discusses emerging EGFR TKIs in EGFR Exon 20–Mutated NSCLC.
Latest:
Karen Masino on Building a Survivorship ProgramKaren Masino, from Ingalls Memorial Hospital, discusses the intricacies of developing a survivorship program.
Latest:
Screening and Management: Distress and the Nurse Navigator, Part IICancer and its treatment creates or aggravates psychosocial distress, while unresolved physical and practical problems can also add to the distress of patients attempting to complete their treatment and recovery.
Latest:
Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast CancerKaren Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.
Latest:
Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial DesignsDr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.
Latest:
Dr. Reckamp on the Significance of ALTA in ALK+ NSCLCKaren L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.
Latest:
Dr Wisinski on Treatment Developments in HR+/HER2– Breast CancerKari Wisinski, MD, discusses treatment development and the current arsenal for patients with hormone receptor–positive, HER2-negative breast cancer.
Latest:
A "Perfect Storm" Drove Independent to Merge With HospitalAs many hard-pressed physician practices have been doing in the present healthcare environment, our oncology practice also had to take a hard look at our operational design, strategy for the future, and sustainability.
Latest:
Dr. Touijer on Surgical Options for Patients with RCCKarim A. Touijer, MD, MPH, surgeon, Memorial Sloan Kettering Cancer Center, discusses the considering factors for surgical options for patients with renal cell carcinoma (RCC).
Latest:
Dr. Fizazi Discusses Updated Data With Darolutamide in CRPCKarim Fizazi, MD, PhD, head, Department of Cancer Medicine, Gustave Roussy Cancer Center, Villejuif, France, discusses updated data with darolutamide in castration-resistant prostate cancer.
Latest:
Dr. Lewis on Sequencing Strategies in MelanomaKarl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing strategies for the treatment of melanoma.
Latest:
Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell TherapyKarl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.
Latest:
Karmanos Cancer Institute Implements New Bar Code Validation Software for Clinical Trial DrugsThe new process checking system makes sure the right drugs are dispensed, improving patient safety.
Latest:
Dr. Konduri on Sequencing Challenges in ALK+ NSCLCKartik Konduri, MD, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer.
Latest:
Dr. Goodman on the Use of SBRT in Locally Advanced Pancreatic CancerKaryn A. Goodman, MD, MS, discusses key toxicity and efficacy data supporting the use of stereotactic body radiation therapy in locally advanced pancreatic cancer.
Latest:
Renowned Gastrointestinal Radiation Oncologist Hired to Lead Clinical Cancer Research at Mount SinaiKaryn Aalami Goodman, MD, MS, an internationally recognized expert on gastrointestinal cancers, has joined the Icahn School of Medicine at Mount Sinai as Associate Director for Clinical Research at The Tisch Cancer Institute. She is also Professor and Vice Chair for Research and Quality in the Department of Radiation Oncology.
Latest:
Dr. Patel on the Importance of BiosimilarsKashyap Patel, MD, president of the Carolina Blood and Cancer Center and medical director of the International Oncology Network, discusses the importance of biosimilars in oncology.
Latest:
Dr. Yao Discusses Sources of Information on Decisions Regarding Contralateral Prophylactic MastectomyKatharine Yao, MD, director, breast surgical program, NorthShore University HealthSystem, Evanston, Illinois, clinical associate professor, surgery, Pritzker School of Medicine, University of Chicago, discusses a prospective study that analyzed the sources of information regarding decisions on contralateral prophylactic mastectomy.
Latest:
Oral Anticoagulants Demonstrate Value in Management of Acute VTEThe optimal anticoagulant takes into consideration a variety of components, including patient preference, the indication for anticoagulation, comorbidities, reversibility, and other factors relevant to the clinical scenario.
Latest:
Dr. Crew on Treatment in Favorable-Risk HER2+ Breast CancerKatherine Crew, MD, MS, discusses treatment for patients with favorable-risk early-stage HER2-positive breast cancer.
Latest:
Dr. Crew on Recent Advances in HER2+ Breast CancerKatherine D. Crew, MD, MS, discusses recent advances made in HER2-positive breast cancer treatment.
Latest:
Novel NGS Test May Enhance Diagnosis and Management of Indeterminate Thyroid NodulesA next-generation sequencing assay has shown promise as a new tool to aid in the diagnosis and treatment of indeterminate thyroid nodules.
Latest:
Dr. Krajewski on Responses With PD-1 Agents in RCCKatherine Krajewski, MD, associate director, physician, Cancer Imaging Program Fellowship, Dana-Farber Cancer Institute, assistant professor of Radiology, Harvard Medical School, discusses the range of responses seen in patients with renal cell carcinoma (RCC) who have received PD-1 agents as treatment.
